Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2502737rdf:typepubmed:Citationlld:pubmed
pubmed-article:2502737lifeskim:mentionsumls-concept:C0348050lld:lifeskim
pubmed-article:2502737lifeskim:mentionsumls-concept:C1709854lld:lifeskim
pubmed-article:2502737lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:2502737lifeskim:mentionsumls-concept:C0004482lld:lifeskim
pubmed-article:2502737lifeskim:mentionsumls-concept:C0010592lld:lifeskim
pubmed-article:2502737lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:2502737lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:2502737lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:2502737lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:2502737lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:2502737pubmed:issue4lld:pubmed
pubmed-article:2502737pubmed:dateCreated1989-8-31lld:pubmed
pubmed-article:2502737pubmed:abstractTextThirty recipients of living related donor kidneys treated either with cyclosporin or azathioprine were evaluated clinically and functionally in a 1-year prospective study. Only the azathioprine group showed either accelerated or chronic rejection (one patient each). The azathioprine patients had higher rate of infectious episodes (P = 0.05), leukopenia (P = 0.003) and steroidal side-effects (P less than 0.007). During the early post-transplant period the renal functional performance was the same in both groups. Afterwards, however, the plasma creatinine was higher in the cyclosporin group (P less than 0.01). Mean arterial pressure remained similar throughout the study in both groups. The anaemia correction was similar in both groups but the haematocrit was greater in the cyclosporin-treated subjects (P less than 0.005).lld:pubmed
pubmed-article:2502737pubmed:languageenglld:pubmed
pubmed-article:2502737pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2502737pubmed:citationSubsetIMlld:pubmed
pubmed-article:2502737pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2502737pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2502737pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2502737pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2502737pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2502737pubmed:statusMEDLINElld:pubmed
pubmed-article:2502737pubmed:issn0931-0509lld:pubmed
pubmed-article:2502737pubmed:authorpubmed-author:JamesEElld:pubmed
pubmed-article:2502737pubmed:authorpubmed-author:MocarquerAAlld:pubmed
pubmed-article:2502737pubmed:authorpubmed-author:ArisLLlld:pubmed
pubmed-article:2502737pubmed:authorpubmed-author:ZehnderCClld:pubmed
pubmed-article:2502737pubmed:authorpubmed-author:AguiloJJlld:pubmed
pubmed-article:2502737pubmed:authorpubmed-author:Morales-Barri...lld:pubmed
pubmed-article:2502737pubmed:authorpubmed-author:TrivinoRRlld:pubmed
pubmed-article:2502737pubmed:issnTypePrintlld:pubmed
pubmed-article:2502737pubmed:volume4lld:pubmed
pubmed-article:2502737pubmed:ownerNLMlld:pubmed
pubmed-article:2502737pubmed:authorsCompleteYlld:pubmed
pubmed-article:2502737pubmed:pagination293-6lld:pubmed
pubmed-article:2502737pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2502737pubmed:meshHeadingpubmed-meshheading:2502737-...lld:pubmed
pubmed-article:2502737pubmed:meshHeadingpubmed-meshheading:2502737-...lld:pubmed
pubmed-article:2502737pubmed:meshHeadingpubmed-meshheading:2502737-...lld:pubmed
pubmed-article:2502737pubmed:meshHeadingpubmed-meshheading:2502737-...lld:pubmed
pubmed-article:2502737pubmed:meshHeadingpubmed-meshheading:2502737-...lld:pubmed
pubmed-article:2502737pubmed:meshHeadingpubmed-meshheading:2502737-...lld:pubmed
pubmed-article:2502737pubmed:meshHeadingpubmed-meshheading:2502737-...lld:pubmed
pubmed-article:2502737pubmed:meshHeadingpubmed-meshheading:2502737-...lld:pubmed
pubmed-article:2502737pubmed:meshHeadingpubmed-meshheading:2502737-...lld:pubmed
pubmed-article:2502737pubmed:meshHeadingpubmed-meshheading:2502737-...lld:pubmed
pubmed-article:2502737pubmed:meshHeadingpubmed-meshheading:2502737-...lld:pubmed
pubmed-article:2502737pubmed:meshHeadingpubmed-meshheading:2502737-...lld:pubmed
pubmed-article:2502737pubmed:meshHeadingpubmed-meshheading:2502737-...lld:pubmed
pubmed-article:2502737pubmed:meshHeadingpubmed-meshheading:2502737-...lld:pubmed
pubmed-article:2502737pubmed:year1989lld:pubmed
pubmed-article:2502737pubmed:articleTitleA prospective one-year study evaluating the clinical outcome of recipients of living donor kidneys treated with cyclosporin and azathioprine.lld:pubmed
pubmed-article:2502737pubmed:affiliationDepartment of Nephrology, Barros Luco Trudeau Hospital, University of Chile, Santiago.lld:pubmed
pubmed-article:2502737pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2502737pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2502737pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:2502737pubmed:publicationTypeControlled Clinical Triallld:pubmed